ELIANSH(SH:600836)2022-04-28 16:00Financial Performance - The company's operating revenue for Q1 2022 was CNY 142,808,254.98, representing a decrease of 43.86% compared to the same period last year[2]. - The net profit attributable to shareholders was CNY 2,177,963.54, down 69.21% year-on-year[2]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 701,997.47, a decline of 86.34% compared to the previous year[2]. - The basic earnings per share were CNY 0.003, reflecting a decrease of 72.73% year-on-year[2]. - Total operating revenue for Q1 2022 was ¥142,808,254.98, a decrease of 43.8% compared to ¥254,369,056.53 in Q1 2021[16]. - Net profit for Q1 2022 was ¥2,239,028.09, a decline of 70.4% from ¥7,558,842.27 in Q1 2021[17]. - Total comprehensive income for Q1 2022 was ¥2,239,028.09, down from ¥7,558,842.27 in Q1 2021[17]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 2,253,003,734.73, an increase of 3.81% from the end of the previous year[3]. - As of March 31, 2022, the company's total assets amounted to approximately CNY 2.25 billion, an increase from CNY 2.17 billion at the end of 2021, reflecting a growth of about 3.8%[12]. - Total liabilities as of Q1 2022 amounted to ¥986,709,650.30, an increase from ¥908,978,819.14 in the previous year[17]. - The total current liabilities were reported at CNY 715.58 million, with short-term borrowings at CNY 476.53 million, a slight decrease from CNY 496.72 million at the end of 2021[12]. Cash Flow - The net cash flow from operating activities was CNY 25,639,497.64, with no applicable year-on-year comparison[2]. - In Q1 2022, the net cash flow from operating activities was ¥25,639,497.64, a significant improvement compared to a net cash outflow of ¥51,692,580.93 in Q1 2021[19]. - Total cash inflow from operating activities in Q1 2022 was ¥822,788,092.56, down 23.4% from ¥1,073,214,140.23 in Q1 2021[19]. - Cash outflow from operating activities decreased to ¥797,148,594.92 in Q1 2022, compared to ¥1,124,906,721.16 in Q1 2021, reflecting a reduction of 29.1%[19]. - The net cash flow from financing activities was negative at -¥34,429,654.42 in Q1 2022, contrasting with a positive cash flow of ¥138,049,473.35 in Q1 2021[20]. Shareholder Information - The company had a total of 33,811 common shareholders at the end of the reporting period[6]. - The largest shareholder, Hangzhou Zhefayilian Business Management Partnership, held 180,468,652 shares, accounting for 26.89% of the total shares, with 127,500,000 shares pledged[6]. - The first major shareholder holds 180,468,652 shares, accounting for 26.89% of the total share capital, with 127,500,000 shares pledged, representing 70.65% of their holdings[8]. Operational Insights - The decline in revenue and profit was primarily due to the impact of the pandemic on the printing and packaging sector and the commercial service sector[4]. - The company is actively conducting nationwide research and planning for pharmaceutical industry and product targets, indicating a strategic focus on market expansion[9]. - The company has signed a letter of intent to acquire at least 30% of Shanghai Baocan New Energy Environmental Technology Co., with an estimated valuation of no less than CNY 450 million[9]. - The company has completed the acquisition of land use rights for a biopharmaceutical industrial base project, covering approximately 106,625 square meters (about 160 acres)[9]. Cost Management - Total operating costs for Q1 2022 were ¥132,938,182.63, down 46.0% from ¥247,160,602.47 in Q1 2021[16]. - Research and development expenses for Q1 2022 were ¥641,038.08, significantly lower than ¥3,450,848.42 in Q1 2021, indicating a reduction in R&D investment[16]. - The company reported a decrease in sales expenses to ¥2,402,331.50 from ¥7,145,294.70 in the previous year, reflecting cost-cutting measures[16].